Olive Oil and 14% Lower CV Risk in 90,000+ US Adults

This 24-year prospective cohort study of 92,978 U.S. adults from the Nurses' Health Study and the Health Professionals Follow-Up Study, published in the Journal of the American College of Cardiology, found that higher olive oil intake was associated with 14% lower cardiovascular disease risk and 18% lower coronary heart disease risk in a non-Mediterranean population.

Why This Study Matters

Olive oil's cardiovascular benefit has been well-documented in Mediterranean populations -- PREDIMED in Spain, EPIC-Spain, the Three-City study in France. The open question for U.S. clinicians and public health authorities has been whether the same association holds outside the Mediterranean dietary matrix. Americans consume far less olive oil than Greeks or Italians, and they consume it embedded in a different overall diet. Whether the dose-response curve translates was the question this paper set out to answer.

This 2020 analysis used the same two Harvard cohorts -- the Nurses' Health Study and the Health Professionals Follow-Up Study -- that subsequently produced the 2022 all-cause mortality paper and the 2024 dementia mortality paper. The 2020 paper focused specifically on cardiovascular endpoints: total cardiovascular disease, coronary heart disease, and stroke. According to PubMed, the paper was published in JACC on March 5, 2020 (DOI: 10.1016/j.jacc.2020.02.036).

The result: 14% lower cardiovascular disease risk and 18% lower coronary heart disease risk among participants consuming more than half a tablespoon (more than 7 g) per day. The effect was driven primarily by coronary heart disease; the association with stroke was not statistically significant.

How It Was Designed

The basics are in the study design bar above: 61,181 women from the Nurses' Health Study and 31,797 men from the Health Professionals Follow-Up Study, 24 years of follow-up, food frequency questionnaire every four years.

The cohorts are among the most carefully maintained in nutrition epidemiology. Participants were free of cancer, heart disease, and stroke at baseline. Dietary intake was assessed by semi-quantitative food frequency questionnaire at baseline in 1990 and every four years thereafter through 2014. The researchers used cumulatively averaged intake rather than baseline-only data, which captures actual long-term exposure and dampens measurement error.

Cox proportional-hazards models adjusted for age, ethnicity, BMI, smoking, physical activity, multivitamin use, family history of myocardial infarction, hypertension, hypercholesterolemia, alcohol intake, menopausal status, and intake of fruits, vegetables, whole grains, red meat, processed meat, and other dietary components. Critically, the analyses also adjusted for total energy intake and total fat intake, isolating olive oil's specific contribution from broader dietary patterns.

The team conducted substitution analyses: rather than just comparing high vs. low olive oil consumers, the researchers modeled what happens when 5 g/day of margarine, butter, mayonnaise, or dairy fat is replaced with the equivalent amount of olive oil. This is the practical question most readers actually have -- what happens if you swap one fat for another in your daily diet.

In a subset of participants, the team also examined the association of olive oil intake with circulating inflammatory biomarkers (CRP, IL-6) and lipid profile measures. This biomarker substudy provides a mechanistic check on the cohort findings.

What They Found

Over 24 years, the study documented 9,797 incident cardiovascular events, including 6,034 coronary heart disease cases and 3,802 stroke cases. Comparing participants in the highest olive oil intake category (more than 0.5 tablespoon/day or more than 7 g/day) to nonconsumers:

Outcome	Hazard Ratio (95% CI)	Risk Reduction	What It Measures
Total CVD	0.86 (0.79-0.94)	14% lower	CHD + stroke + other CVD
Coronary heart disease	0.82 (0.73-0.91)	18% lower	MI + fatal CHD
Total stroke	Not significant	--	Ischemic + hemorrhagic
Replace 5 g/d animal/processed fat	5-7% lower CVD/CHD	5-7% lower	Substitution analysis

Green indicates a favorable direction vs. low/no olive oil intake. Cardiovascular disease and coronary heart disease hazard ratios are statistically significant; 95% confidence intervals exclude 1.0. The stroke association was not significant.

The substitution analyses showed that replacing 5 g/day of margarine, butter, mayonnaise, or dairy fat with the equivalent amount of olive oil was associated with 5% to 7% lower risk of total CVD and CHD. Substituting olive oil for other vegetable oils combined did not show a significant association -- consistent with the pattern in the later 2022 paper, where the cleanest benefit comes from replacing animal and industrial fats rather than other plant oils.

In the biomarker substudy, higher olive oil intake was associated with lower circulating inflammatory markers (CRP, IL-6) and a more favorable lipid profile. That biomarker evidence provides mechanistic plausibility for the epidemiologic association.

Reading the Results

CHD versus stroke. The 18% reduction in coronary heart disease and the null finding for stroke are biologically informative. CHD is driven primarily by atherosclerotic plaque buildup in coronary arteries, a process directly affected by oxidized LDL and chronic vascular inflammation. Olive oil polyphenols reduce both. Stroke is a more heterogeneous endpoint -- it includes hemorrhagic events with substantially different etiology -- so a smaller or null association is consistent with the mechanism. The 2022 follow-up from the same cohorts (which focused on mortality) similarly found a stronger signal for ischemic outcomes than for hemorrhagic ones.

The dose threshold. The benefit emerged at intake levels above 7 g/day -- roughly half a tablespoon. That is far below typical Mediterranean-population intake (often 30 to 50 g/day) but within practical reach for U.S. adults willing to swap their primary cooking fat. The 14% CV risk reduction at this modest dose is one of the most actionable findings in the olive oil literature.

The substitution insight. Replacing margarine, butter, mayonnaise, or dairy fat with olive oil produced 5 to 7% lower risk; replacing other vegetable oils did not. The interpretation is that olive oil's edge is not primarily about its monounsaturated fatty acid profile -- because other vegetable oils have similar or better fatty acid profiles. The edge is about what olive oil also contains: phenolic compounds, vitamin E, and squalene, none of which are present in animal fats or industrial spreads. That points back to the polyphenol mechanism documented in EUROLIVE and confirmed in the 2019 meta-analysis of 26 RCTs.

What Didn't Change

The stroke association was not statistically significant. The substitution comparison of olive oil vs. other vegetable oils combined showed no significant difference. These are important null findings: the data do not establish olive oil as superior to canola, sunflower, or other plant oils for cardiovascular outcomes in U.S. adults. The comparison that drives the benefit is olive oil versus animal-derived and processed fats.

The study is observational. It cannot prove that consuming more olive oil causes lower cardiovascular risk. The associations could reflect residual confounding by socioeconomic factors, health-conscious behavior, or unmeasured dietary patterns. The multivariable adjustment is extensive but cannot eliminate this possibility entirely. PREDIMED and CORDIOPREV -- both RCTs -- provide the causal evidence that complements this observational data.

Broader Context

This 2020 paper is the cardiovascular-specific predecessor to the broader 2022 mortality analysis by Guasch-Ferre et al. in JACC (which reported 19% lower all-cause mortality, 19% lower cardiovascular mortality, and 29% lower neurodegenerative mortality at the same intake threshold) and to the 2024 JAMA Network Open paper by Tessier et al. (which reported 28% lower dementia mortality). The three papers together use overlapping cohort data but address different outcomes; this 2020 paper is the cardiovascular-event analysis specifically.

PREDIMED (Estruch et al., NEJM 2018 republished) provides the RCT-quality complement. PREDIMED reported a 31% reduction in major cardiovascular events with a Mediterranean diet supplemented with EVOO in 7,447 high-risk Spanish adults over 4.8 years. CORDIOPREV (Delgado-Lista et al., The Lancet 2022) extended that finding to secondary prevention in patients with established coronary heart disease over 7 years.

The 2011 European Food Safety Authority opinion (Regulation 432/2012) authorized a health claim for olive oil polyphenols and protection of blood lipids from oxidative damage at 5 mg/day of hydroxytyrosol and derivatives. The 7 g/day intake threshold identified in this Harvard cohort analysis approaches the lower end of what would supply the EFSA-recognized polyphenol dose, depending on the specific oil's phenolic content.

Related Research

Continue exploring olive oil and polyphenol science:

• Olive Oil and 19% Lower Mortality in 92,383 U.S. Adults Over 28 Years
• Olive Oil Linked to 28% Lower Dementia Death in 92,383 Adults
• Italian Cohort: Olive Oil Linked to Lower Cancer, CV and All-Cause Mortality

Source: View the original study on PubMed

Olivea's Dosage

This study identified a cardiovascular benefit beginning at more than 7 g/day of olive oil -- roughly half a tablespoon. A single tablespoon of Olivea extra virgin olive oil delivers approximately 14 grams, comfortably above the study threshold. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving in an EVOO matrix; our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.

Editorial Information

Research note. This article summarizes third-party research published in a peer-reviewed journal. Olivea did not conduct or fund the study. Findings reflect the cited paper only and do not establish efficacy of Olivea products.

.